Group Leader/s
Head of lab
intro
The Advanced Therapies group applies the latest gene editing, induced pluripotent stem cells (iPSCs) and organoid technologies to design and validation of new therapies. Our line of work includes the development of new molecular tools to guarantee the safety of in vitro differentiated tissue transplants, the implementation of genomic repair systems for hereditary mutations, and the design of cellular therapies for any disease that could be tackled by modifying the genome of living cells. In particular, we are currently running projects on Alzheimer´s disease and Cancer Immunotherapy
Members
| Daniel Bachiller Pérez |
| Serhii GONCHAROV |
| Aranzazu Manzano Perez |
| Seyedeh Neda Mousavy Gharavy |
| Jose Maria Martin Fernandez |
| Laura Tabuenca Mosteo |
| Diego Lopez Montes |
Funding
Ongoing Support
CPP2022-009594. Bioengineering of induced pluripotent stem cells for advanced immunotherapy for fungal infections. (EPIFIN). Spanish Ministry of Science. 01/01/2024 - 31/12/2026
CA21151. Generation of human induced pluripotent stem cells from haplo-selected cord blood samples (Haplo-iPS). European Cooperation in Science and Technology-COST ACTION 11/10/2022 - 10/10/26
OC-2020-1-24729. Genome Editing to Treat Human Diseases (GenE-Humdi). European Cooperation in Science and Technology- COST ACTION. 01/10/2022-0/09/2026.
CPP2021-008350. Next-Generation Off-The-Shelf CAR-NK iPS derived cells from for allogeneic immunotherapy of solid tumors. OSCAR-iNK. 01/11/2022-31/10/2025.
The project CPP2021-008350 is funded by MCIN/AEI/10.13039/501100011033 and by the European Union NextGenerationEU/ PRTR
PI21/00393. Design and production of universal off-the-shelf CAR-NK cells derived from iPSCs for cancer immunotherapy. Subproject 2: Design and implementation of an innovative technology for loading CARs. Carlos III Insitute of Health. (01/01/2022-31/12/2024.
UCRAN20059. Development of a multi-organ-on-a-chip microfluidic platform for in vitro study of neurodegenerative diseases. (CSIC Scientific Cooperation Program with Ukraine). 01/07/2022-30/06/2024.
Y2020/NMT-63122. Development of a multi-organ-on-a-chip microfluidic platform for in vitro study of neurodegenerative diseases. Autonomous Region of Madrid. 01/07/2021-30/06/2024.
Completed support
INTER200005. Strengthening of Regional Health Systems through a Latin American Network for Exchange of Knowledge in Advanced Therapies. Spanish National Research Council (CSIC) and Spanish Agency for International Development Cooperation (AECID). 01/01/2021-
31/12/2023.
PRD2018/87. Use of next-generation viral vectors (SENDAI) in the treatment of AIDS through genomic editing. Government of the Balearic Islands. 01/07/2020-01/07/2023.
EIN2020-112365. Europa Investigación: ayuda para la coordinación de un proyecto del Programa Horizonte Europa. Spanish Ministry of Science. 01/01/2021-31/12/2022.
PI18/00334 Optimización de una terapia combinada genómica y celular para el tratamiento del SIDA.
Carlos III Institute of Health. 01/01/2019-31/12/2021.
RTC-2017-6696-1. Sustitutos de Córnea Bioingenierizada innovadores y eficaces basados en tecnologías combinadas de Terapia Celular y Nanotecnología. NANOGROW. Spanish Ministry of Science. 15/12/2017-31/12/2020.
RTC-2016-5324-1 Nuevas herramientas de ingeniería genómica para el tratamiento del SIDA (STOP-SIDA). Spanish Ministry of Science. 01/06/2015-31/12/2019.
GA No.667079. Novel therapeutic approaches for the treatment of Cystic Fibrosis based on small molecule transmembrane anion transporters. European Commission. 01/01/2016- 31/12/2018.
PI14/01073. La Fibrosis Quística como modelo para la aplicación de terapias avanzadas al tratamiento de las enfermedades raras y su adaptación a la práctica clínica. Carlos III Institute of Health. 01/01/2015-31/12/2017.
RTC-2014-2207-1 TERARMET: Desarrollo de Terapias para el Tratamiento de enfermedades raras. Spanish Ministry of Science. (28/01/2014- 31/12/2017).
Corrección mediante ingeniería genómica del gen CFTR en células iPS de pacientes con Fibrosis Quística. Salud 2000 Foundation. 01/05/2014-30/04/2017.
Pluripotent Stem Cell based gene therapy for Cystic Fibrosis. Mutua Madrileña Foundation. 26/09/2014- 26/09/2015.
FP7-PEOPLE-2010-IEF: GOODCELLS. Marie-Curie grant. European Commission. /07/2012-20/07/2014.
IPT-2011-1402-900000 Investigación integral de terapias efectivas para el tratamiento de la Fibrosis Quística. Spanish Ministry of Science. 2011-2014.
PLE2009-0091. Pluripotent Stem-Cell Based Gene Therapy for Cystic Fibrosis. Spanish Ministry of Science. (FISIB-CSIC). 2009-2012.
PI07/124. Bases moleculares del enfisema pulmonar. Desarrollo de un modelo experimental en ratones transgénicos. Carlos III Institute of Health. 01/01/2008-31/12/2010.
Desarrollo de un protocolo combinado de terapia génica y terapia celular para el tratamiento de la Fibrosis Quística. Government of the Balearic Islands. 2009-2010
200720I041. Caracterización y análisis genético de las células madre del pulmón. (CSIC). 2009-2009
Identificación mediante marcaje genético de linajes celulares y células madre del pulmón. Mutua Madrileña Foundation. 2007-2009.
PROGECIB-49A. Identificación de factores que inducen la diferenciación de células madre a epitelio pulmonar. Government of the Balearic Islands. 01/01/2007-31/12/2008.
PI04/2360. Análisis genético y células madre del pulmón. Carlos III Institute of Health. 01/01/2006-31/12/2007.
PI05/2587. Bases moleculares del enfisema pulmonar. Desarrollo de un modelo experimental en ratones transgénicos. Carlos III Institute of Health. 01/01/2006-31/12/2007.
CP04/00124. Subprograma Miguel Servet. Carlos III Institute of Health. 01/01/2005-31/12/2007.
Transducin (b)like 1 (TBL1) in late-onset degenerative hearing loss. National Institute of Health (NIH)-NIDCD. (UCLA. 01/12/2004-30/11/2007.
BMP Signaling in DiGeorge Syndrome Mouse Models. The Children´s Heart Foundation. (University of California (UCLA)). 01/01/2005-31/12/2006.
The Chordin/BMP pathway in cerebellum development. UCLA Faculty Grant Program. (University
of California, UCLA). 2004-2005.
Genetic Analysis of the chordin/BMP pathway in the inner ear. National Organization for Hearing Research (NOHR). (UCLA). 01/01/2004-31/12/2004.
Sensory coding among semicircular canal afferent neurons; RO1 DcC05059. National Institute of Health (NIH)-NICCD. 01/01/2004-31/12/2004.
Molecular basis of hearing loss. UCLA Chancellors office Joint Faculty Award. University of California (UCLA). 01/01/2003-31/12/2003.
Targeted inactivation of the tbl1 gene in mouse. Stein-Oppenheimer Fund. (University of California UCLA). 01/01/2002-31/12/2003.
More info
Patents
1. Gainza E, del Pozo A, Gainza G, Ibarrola O, Villullas O, Fernández R, Bachiller D, Pedraz JL, Esquisabel A, Pastor M, Fusté E, Serramitjana E, Martín I. PCT/ES2014/070538. Lipid nanoparticle of Polymyxin. USA. 03/20/2018.
2. Gainza E, Gainza G, Del Pozo A, Pastor M, Pedraz JL, Viñas M, Bachiller D. Gálvez V. P201530874. Nucleic acid molecule, fusion protein and method for modifying the genetic material of a cell. European Union. 19/06/2015.
3. Gainza E, Villulas S, Ibarrola O, Gainza G, Herrán E, Aguirre JJ, Del Pozo A, Pedraz JL, Esquisabel A, Moreno M, Pastor M, Viñas M, Vinuesa MT, Bachiller D. P201431894. Lipid nanoparticle of Tobramycin. Spain. 12/19/2014.
4. Bachiller D, Palomino E. P201831126. Safe harbor site for the introduction of genetic information in cell by site-specific integration system. Spain. 20/11/2018.
5. Bachiller D, Fleischer A, Vallejo S. EP18382792. Double and Inducible suicide gene construct and its use in gene therapy. Spain. 07/11/2018.
ACKNOWLEDGEMENTS
Ayuda EIN2020-112365 financiada por MCI/AEI/10.13039/501100011033 y por la Unión Europea Next GenerationEU/PRTR